Treatment of Heparin-Induced Thrombocytopenia
نویسندگان
چکیده
منابع مشابه
Heparin induced thrombocytopenia
Abstract Background and Objectives Heparin is still a commonly used anticoagulant in prophylaxis and treatment of thromboembolic events. Heparin-induced thrombocytopenia (HIT) is a life-threating adverse drug reaction of heparin. The diagnosis of HIT is made based on two important criteria, firstly clinical evaluation and secondly laboratory testing. In this comprehensive review, the authors w...
متن کاملTreatment of heparin-induced thrombocytopenia.
OBJECTIVE To describe heparin-induced thrombocytopenia (HIT or HIT-2), an immune-mediated adverse reaction to heparin or low-molecular-weight heparin. Available treatment options and considerations in developing a therapy approach are discussed. DATA SOURCES A search of the National Library of Medicine (1992-June 2001) was done to identify pertinent literature. Additional references were revi...
متن کاملTreatment and Prevention of Heparin-Induced Thrombocytopenia
2.1.1. For patients receiving heparin in whom clinicians consider the risk of HIT to be . 1%, we suggest that platelet count monitoring be performed every 2 or 3 days from day 4 to day 14 Background: Heparin-induced thrombocytopenia (HIT) is an antibody-mediated adverse drug reaction that can lead to devastating thromboembolic complications, including pulmonary embolism, ischemic limb necrosis ...
متن کاملNew treatment options for heparin-induced thrombocytopenia.
A rapidly acting anticoagulant that can either inhibit thrombin generation or inhibit thrombin itself is the optimum therapy for acute thrombosis associated with heparin-induced thrombocytopenia (HIT). In this review, the newer treatment approaches that fulfill this requirement are discussed. These newer treatments include hirudin and argatroban, direct thrombin inhibitors, and danaparoid, whic...
متن کاملHeparin-induced thrombocytopenia.
Heparin-induced thrombocytopenia (HIT) is an immune complication of heparin therapy caused by antibodies to complexes of platelet factor 4 (PF4) and heparin. Pathogenic antibodies to PF4/heparin bind and activate cellular FcγRIIA on platelets and monocytes to propagate a hypercoagulable state culminating in life-threatening thrombosis. It is now recognized that anti-PF4/heparin antibodies devel...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Archives of Internal Medicine
سال: 2004
ISSN: 0003-9926
DOI: 10.1001/archinte.164.4.361